There is a lot of commentary about the poor performance of the biotech section in 2021 mainly due a policy change of the Biden administration. The view is that the biotech sector is now deeply undervalued and the policy changes were overreacted. There’s a view that 2022 will be a good year for biotech in the US and for us it’s should be as well with Lag-3 coming to the forefront hopefully BMS will get FDA approval in March for their Lag-3 drug. I’ve top up considerably at .47 cents to me it’s the biggest Christmas gift !!!
Trust everyone had a great Christmas and I personally feel 2022 will be a much better year for the Immutep share price….
Media, page-26
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |